Antonio Rullan

16PUBLICATIONS
64CO-AUTHORS
Molecular targetsPredictive and prognostic markersChemotherapyCancer therapy (excl. chemotherapy and radiation therapy)Epidemiological methods
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Jul 30, 2026
"SMAC"-down for the apoptosis-restoring drug, Xevinapant: What does its story reveal?

|Apr 27, 2026
Tissue-specific fibroblast lipid cues impose the rate of epithelial cancer invasion.

|Oct 22, 2025
Xevinapant plus Chemoradiotherapy Negatively Sculpts the Tumor-Immune Microenvironment in Head and Neck Cancer.

Charleen Chan Wah Hak, Emmanuel C Patin, Anton Patrikeev

|Sep 26, 2025
Addition of oncolytic virotherapy to clinical isolated limb perfusion for melanoma and sarcoma activates antitumor immunity.

Andrew J Hayes, Emma J Davies, Michelle Wilkinson

|Jul 08, 2025
The PARP inhibitor talazoparib synergizes with reovirus to induce cancer killing and tumour control in vivo in mouse models.

Joan Kyula-Currie, Victoria Roulstone, James Wright

|May 24, 2025
Palbociclib and dsRNA sensor co-operate to enhance anti-cancer effects through ER stress and modulation of immune evasion.

Victoria Roulstone, Joan Kyula-Currie, James Wright

Pageof 3

Frequent Collaborators

8 joint publications

Kevin J Harrington

6 joint publications

Alan Melcher

6 joint publications

Emmanuel Christian Patin

6 joint publications

Charleen Chan Wah Hak